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IL-5 is a Th2 cytokine which activates eosinophils and is suggested to have an atheroprotective role.
Genetic variants in the IL5 locus have been associated with increased risk of CAD and ischemic stroke.
In this study we aimed to identify genetic variants associated with IL-5 concentrations and apply a
Mendelian randomisation approach to assess IL-5 levels for causal effect on intima-media thickness in
a European population at high risk of coronary artery disease. We analysed SNPs within robustly associ-
ated candidate loci for immune, inflammatory, metabolic and cardiovascular traits. We identified 2
genetic loci for IL-5 levels (chromosome 5, rs56183820, BETA = 0.11, P = 6.73E5 and chromosome 14,
rs4902762, BETA = 0.12, P = 5.76E6) and one for eosinophil count (rs72797327, BETA = 0.10,
P = 1.41E6). Both chromosome 5 loci were in the vicinity of the IL5 gene, however the association with
IL-5 levels failed to replicate in a meta-analysis of 2 independent cohorts (rs56183820, BETA = 0.04,
P = 0.2763, I2 = 24, I2  P = 0.2516). No significant associations were observed between SNPs associated
with IL-5 levels or eosinophil count and IMT measures. Expression quantitative trait analyses indicate
effects of the IL-5 and eosinophil-associated SNPs on RAD50 mRNA expression levels (rs12652920
(r2 = 0.93 with rs56183820) BETA = 0.10, P = 8.64E6 and rs11739623 (r2 = 0.96 with rs72797327)
BETA = 0.23, P = 1.74E29, respectively). Our data do not support a role for IL-5 levels and eosinophil
count in intima-media thickness, however SNPs associated with IL-5 and eosinophils might influence sta-
bility of the atherosclerotic plaque via modulation of RAD50 levels.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Atherosclerosis is a process leading to coronary artery disease
(CAD) and ischemic stroke, and is among the leading causes of
mortality and morbidity throughout the world [1]. It is thought
that a key component of atherosclerosis is lipid accumulation in
the arterial wall, leading to leukocyte recruitment, inflammation
2 O. McLeod et al. / Cytokine 81 (2016) 1–9and participation of both innate and adaptive immune responses.
To support the immune responses hypothesis, a number of
immune or inflammatory biomarkers for cardiovascular disease
(CVD) have been investigated. Some, such as C-reactive protein
(CRP), appear to reflect general disease processes [2,3], whereas a
number of cytokines (such as IL-1, IL-2, IL-6, IL-8, IL-10, IL-12,
IL-17 and TNFa) are robustly associated with CVD and are thought
to be actively involved in the inflammatory processes leading to
atherosclerosis [4,5].
Genetic studies have identified single nucleotide polymor-
phisms (SNPs) that are associated with increased risk of CAD in
the interleukin-5 gene (IL5) [6] and increased risk of ischemic
stroke in the interleukin-5 receptor alpha subunit gene (IL5RA)
[7]. As with most genetic variants associated with CVD, the mech-
anism by which the IL5 SNP influences disease is unclear. A number
of studies (including one from our group) have also proposed an
athero-protective role for IL-5 [8–11], which is supported by the
fact that it is produced mainly by anti-inflammatory T helper 2
(Th2) cells.
In addition to activated Th2 cells, IL-5 can be produced by mast
cells and to a lesser extent by eosinophils. IL-5 is a growth and
differentiation factor for B-cells, an immunoglobulin-A (IgA)-
enhancing factor and a key cytokine in eosinophil maturation, dif-
ferentiation, activation and survival [12,13]; thus, it is interesting
that the IL5 locus has also been associated with eosinophil count
[14]. Cellular responses are dependent upon IL-5 activating a
dimeric receptor consisting of an a and a b-subunit. The
b-subunit is shared with IL-3 and granulocyte–macrophage
colony-stimulating factor (GM-CSF) [15], however the a-subunit
is specific to IL-5. Thus, availability of the a-chain on the cell
surface controls responsiveness of the cell to IL-5 [16,17].
Thickness of the intima-media layer of the carotid artery can be
considered a marker of cardiovascular risk. Differences in carotid
intima-media thickness (IMT) over time can be indicative of
changes in the structure, and possibly functions, of the vessel wall.
The aims of this study were to identify genetic variants associated
with IL-5 levels and to use these in a Mendelian randomisation
approach to assess IL-5 levels for causal effects on carotid IMT.
As eosinophil count and IL-5 levels are inter-related, we also inves-
tigated the genetic regulation of eosinophil count. We used the
prospective IMPROVE study (the Carotid Intima Media Thickness
[IMT] and IMT-Progression as Predictors of Vascular Events in a
High Risk European Population study), which is based on 3703 sub-
jects at high risk of CVD with extensive genetic data, biochemical
phenotyping and repeat detailed ultra-sound measurements of
the carotid artery IMT [18,19]. Genetic markers robustly associated
with increased levels of a biomarker or constituting a causal com-
ponent of increased IMT should be useful for risk stratification and
early prevention of CVD.
2. Materials and methods
2.1. Discovery cohort: the IMPROVE cohort
The design features, biobank and dataset of the IMPROVE study
have been reported [18,19]. Of 3703 participants with at least three
cardiovascular risk factors but without symptoms or diagnosed
prevalent disease, 3435 passed phenotypic quality control and
were considered for the current study. Ethics committee approval
for the study was obtained from each centre and written informed
consent was obtained from all participants.
2.2. Phenotypes
A wide range of anthropometric and biochemical measure-
ments were acquired, including fasting concentrations of HDLand LDL cholesterol (by Friedewald’s formula), triacylglycerol
(TG), high sensitivity CRP (hs-CRP), creatinine and plasma glucose
as described [19]. Diabetes was defined as diagnosis of diabetes
and/or fasting blood glucose P7 mmol/L and/or glucose lowering
treatment. Levels of IL-5 were measured in EDTA-plasma samples
using the ultra-sensitive kit for human IL-5 (MesoScale Discovery,
Gaithersburg, MD, USA) following instructions provided by the
manufacturer. Details of the high-resolution ultrasound measure-
ments of carotid IMT at baseline and follow-up have been reported
[18,19]. A number of studies suggested that atherosclerotic
changes can be site-specific and have distinct clinical implications
[20–22]. Thus one composite and four segment-specific measure-
ments of carotid IMT by were included in the study: IMTmean-max
(mean of the maximum IMT measures along the entire carotid
tree), IMT-CCmean and IMT-CCmax (mean and maximum of common
carotid segment), IMT-BIFmean and IMT-BIFmax (mean and maxi-
mum of the bifurcation). The ultrasonographic measurements
were obtained at baseline and after 15 and 30 months. These three
time points were used in linear regression to assess change over
time in IMT [18], referred to here as progression of IMT. Character-
istics of the IMPROVE cohort with available genetic and phenotypic
data (n = 3435) are presented in Table 1.
2.3. Genetic analysis
Genotyping was performed using Illumina 200 K Cardio-
Metabochip [23] and Immunochip [24] genotyping arrays (hence
referred to as the combined chip). Whilst the combined chips do
not have genome-wide coverage, they do have good coverage of
candidate or robustly associated loci for immune, inflammatory,
metabolic and cardiovascular traits, which allows for a less conser-
vative threshold for significance compared to genome-wide plat-
forms. Genotyping and calling were performed at the SNP
Technology Platform (Uppsala University, Sweden Uppsala).
Standard genetic quality control procedures were followed with
exclusions for SNPs failing call rate (<95%) and Hardy–Weinberg
(p < 5E7) checks or with minor allele frequency (MAF) <1% and
for subjects with cryptic relatedness or sex check failures. After
quality control, 3433 individuals with genetic and phenotypic data
were included in the analysis.
2.4. Replication cohorts: the PROCARDIS and MDC cohorts
Replication was sought in the PROCARDIS [25] and MDC cohorts
[26,27].
The PROCARDIS cohort consists of cases and controls from the
UK, Sweden, Italy and Germany. All cases were diagnosed with
CAD before the age of 66 years and most (80%) had a sibling with
CAD before 66 years. Controls were recruited from the same
populations and did not have a diagnosis of CAD, or a sibling with
diagnosis of CAD, before 66 years of age. Plasma levels of IL-5
were measured in duplicate on the same plate by a sandwich
immunoassay with electrochemiluminescence detection using a
MesoScale Diagnostics platform (Gaithersburg, Maryland, USA).
Genomewide genotyping of PROCARDIS was conducting using
the Illumina 1 M or 610 K platforms. Genotype calling was per-
formed at the Centre National du Genotypage, Paris or the Uppsala
SNP Genotyping platform, Sweden. Standard quality control was
conducted as detailed above.
The Malmö Diet and Cancer (MDC) study is a prospective
population-based cohort study including 28,449 subjects recruited
during 1991–1996. Subjects aged 45–69 years, living in Malmö,
Sweden were eligible for participation. Between November 1991
and February 1994, every second enrolled subject was also invited
to take part in a substudy of the epidemiology of carotid artery dis-
ease. This MDC-CardioVascular cohort consists of 6103 subjects
Table 1
Clinical characteristics of the IMPROVE cohort.
All subjects Males Females P-valuea
3435 1662 1773
Age (years) 64.5 (59.6–67.2) 64.3 (59.4–67.1) 64.7 (59.9–67.3) 0.030
Height (m) 1.67 (1.6–1.74) 1.74 (1.70–1.79) 1.60 (1.57–1.65) <0.001
BMI (kg/m2) 26.8 (24.3–29.5) 27.1 (25.0–29.3) 26.4 (23.5–29.7) <0.001
Waist/hip ratio 94 (86–102) 0.96 (0.93–1.01) 0.87 (0.82–0.91) <0.001
SBP (mmHg) 140 (130–153) 141 (130–154) 140 (130–152) 0.260
DBP (mmHg) 81 (75–88) 82 (77–90) 80 (75–88) <0.001
Hypertension (%) 2471 (72.0) 1168 (70.3) 1303 (73.5) 0.020
Total cholesterol (mmol/L) 5.44 (4.69–6.24) 5.20 (4.52–5.94) 5.67 (4.89–6.45) <0.001
LDL-cholesterol (mmol/L) 3.5 (2.82–4.22) 3.37 (2.74–4.02) 3.65 (2.94–4.39) <0.001
HDL-cholesterol (mmol/L) 1.2 (1.01–1.46) 1.10 (0.93–1.30) 1.32 (1.11–1.60) <0.001
Triglycerides (mmol/L) 1.31 (0.94–1.9) 1.37 (0.97–2.02) 1.26 (0.91–1.79) <0.001
Fasting glucose (mmol/L) 5.5 (5–6.3) 5.7 (5.2–6.6) 795.3 (4.8–6.0) <0.001
Diabetes mellitus (%) 904 (26.8) 525 (32.2) 379 (21.7) <0.001
CRP (mg/L) 1.86 (0.77–3.58) 1.63 (0.67–3.25) 2.10 (0.91–3.92) <0.001
Current smokers (%) 515 (15.0) 276 (16.6) 239 (13.5) 0.006
Vitamin D (nmol/L) 48 (34–64) 50 (37–65) 47 (30–62) <0.001
IL-5 (pg/mL) 0.43 (0.27–0.71) 0.48 (0.30–0.76) 0.39 (0.25–0.64) <0.001
Eosinophils (%) 2.6 (1.7–4.0) 2.8 (1.8–4.1) 2.5 (1.6–3.8) <0.001
Framingham risk score 0.23 (0.15–0.35) 0.32 (0.23–0.45) 0.16 (0.11–0.24) <0.001
Lipid-lowering therapy (%) 1675 (49.6) 785 (48.2) 890 (50.9) 0.060
Anti-hypertensive therapy (%) 1936 (56.4) 897 (54.0) 1039 (58.6) 0.005
Baseline IMT
IMTmean 0.85 (0.74–1) 0.90 (0.78–1.06) 0.80 (0.71–0.93) <0.001
IMTmax 1.85 (1.39–2.5) 2.03 (1.55–2.68) 1.74 (1.30–2.31) <0.001
IMTmean-max 1.19 (1.04–1.41) 1.27 (1.09–1.51) 1.13 (0.99–1.31) <0.001
IMT-CCmean 0.71 (0.65–0.8) 0.74 (0.66–0.83) 0.70 (0.64–0.77) <0.001
IMT-CCmax 1.07 (0.96–1.3) 1.13 (0.98–1.40) 1.03 (0.94–1.19) <0.001
IMT-BIFmean 1.06 (0.85–1.34) 1.12 (0.91–1.45) 1.00 (0.80–1.24) <0.001
IMT-BIFmax 1.67 (1.3–2.22) 1.84 (1.39–2.41) 1.57 (1.26–2.13) <0.001
IMT progression
IMTmean 0.017 (0.0001–0.036) 0.019 (0.0002–0.039) 0.015 (0.0001–0.032) 0.004
IMTmax 0.036 (0.035–0.112) 0.036 (0.036–0.116) 0.034 (0.033–0.108) 0.110
IMTmean-max 0.021 (0.005–0.051) 0.024 (0.003–0.058) 0.019 (0.005–0.047) <0.001
IMT-CCmean 0.007 (0.006–0.022) 0.009 (0.006–0.025) 0.006 (0.006–0.020) 0.006
IMT-CCmax 0.007 (0.020–0.042) 0.011 (0.023–0.050) 0.004 (0.019–0.039) 0.010
IMT-BIFmean 0.029 (0.004–0.069) 0.031 (0.005–0.073) 0.027 (0.003–0.066) 0.230
IMT-BIFmax 0.036 (0.020–0.113) 0.037 (0.028–0.114) 0.036 (0.012–0.112) 0.590
Where: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive
protein. Hypertension: diagnosis of hypertension and/or treatment with antihypertensive drugs; Diabetes: diagnosis of diabetes and/or treatment with insulin or other
hypoglycemic drug, and/or fasting glucoseP7 mmol/L at the baseline examination. Values are expressed as median (interquartile range) or number of subjects in group (%).
a P-values between two groups were calculated by Mann–Whitney U test for continuous variables, and by Fisher’s exact test for binary variables.
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under standardized fasting conditions. MDC was genotyped using
the Illumina OmniExpressExome chip and standard quality control
was conducted as detailed above. The methodology used for mea-
suring IL-5 levels has previously been described [28]. Briefly, levels
of cytokines released by mononuclear cells after stimulation (with
CD3/CD28 beads) were analysed using a multiplex cytokine
immunoassay (MesoScale Discovery, Gaithersburg, MD, USA).
Whilst the genotyping platforms utilised by the discovery and
replication cohorts are not the same, all 3 platforms are produced
by the same company and based upon the same bead chip technol-
ogy. In addition, the same quality control parameters are used for
the genotype calling, as well as for the downstream analyses (as
detailed above).
2.5. Statistical methods
Differences between two groups according to sex were assessed
by Wilcoxon Mann–Whitney ranksum test for continuous vari-
ables and Fisher’s exact test for binary variables (Table 1). Since a
sex difference in IL-5 levels has been observed [11], we adjusted
for sex. Risk factors and biomarkers significantly associated with
plasma levels of IL-5 (by Spearman rank correlation) were consid-
ered for inclusion in regression models. Variables with skewed dis-
tributions were log-transformed prior to regression analysis. Inboth the analyses of IL-5 and of eosinophil count, the basic model
was adjusted for population structure (as assessed by the first 3
multi-dimensional scaling components), age and sex. For IL-5 anal-
yses, the extended model also included LDL and hsCRP. For eosino-
phil count, the extended model included BMI, fasting proinsulin
concentration and white blood count. Variables for inclusion in
the extended model were determined by backward stepwise selec-
tion in a multiple regression model. Linear regression analysis was
used to assess associations between SNP genotypes and plasma IL-
5 concentrations or eosinophil count, assuming an additive genetic
model. The threshold for replication was set at p < 1.00E5,
whereas array-wide significance was set at p < 1.92E7 (based on
the calculation of the number of uncorrelated SNPs on the com-
bined Metabo-Immuno chips as previously described [29]). Linear
regression assuming an additive genetic model was also used for
analysis of IMT measures, with adjustment for age, sex and popu-
lation structure. Further adjustment for established CVD risk mark-
ers included age, sex, population structure, BMI, SBP, HDL, TG,
hsCRP, current smoking and type 2 diabetes.
Replication analyses were conducted in the same manner as the
discovery analyses, but the models were amended for PROCARDIS,
where country was used instead of MDS components and case-
control status was included as a covariate. Statistical analyses were
performed in STATA (Statacorp, Houston, TX, USA) except chip-
wide genetic analyses which were conducted using PLINK [30].
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segments [19], correction for testing multiple phenotypes was not
applied.
2.6. Gene expression analysis
Differential gene expression analysis for SNPs robustly associ-
ated with plasma IL-5 concentrations was performed. Firstly, in
the Advanced Study of Aortic Pathology (ASAP) [31], where aortic
adventitia (n = 132), aortic media (n = 137) and heart (n = 127) tis-
sue samples were analysed. In brief, tissue samples were collected
from patients undergoing elective surgery for aortic aneurysm and/
or aortic valve repair. RNA was extracted from biopsy material and
hybridised to Affymetrix ST 1.0 exon arrays (Santa Clara, CA, USA).
DNA was extracted from whole blood and genotyped on the Illu-
mina 610 W-Quad Bead Array (San Diego, CA, USA). SNPs with call
rate >95% were used for imputation, and imputed SNPs with qual-
ity scores of MACH <0.3 were excluded. The ASAP study was
approved by the ethics committee at Karolinska Institutet. Associ-
ations between SNP genotypes and gene expression were assessed
assuming an additive genetic model. Significance was set at
p < 0.0056 (Bonferroni-correction for 3 SNPs in 3 tissues). Secondly
the publicly available MuTHER gene expression data was also
interrogated [32]. Of the IL-5 or eosinophil-associated SNPs identi-
fied in IMPROVE, 5 were available in the MuTHER dataset, thus
p < 0.01 (Bonferroni-correction for 5 SNPs in one tissue) was set
for the level of significance. Finally, the publically available
rSNPBase [33] was searched effects of SNPs on gene expression.
As the data in this resource is qualitative, no threshold for signifi-
cance was employed.3. Results
3.1. Cardiovascular, metabolic, inflammatory or immune-associated
SNPs vs IL-5 levels or eosinophil count
In order to assess whether there are SNPs in loci previously
associated with immune, inflammatory, metabolic or CVD traits
which influence plasma levels of IL-5 or eosinophil count, the com-
bined chip was analysed. When considering IL-5 levels, there were
no genetic variants that demonstrated array-wide significant asso-
ciations (i.e. p < 1.92E7), however 2 loci reached the threshold set
for replication (p < 1.00E5, Fig. 1, Upper panel and Table 2). Fur-
ther adjustment using the extended model had a negligible effect
on the results (Table 2). The chromosome 14 locus consists of a sin-
gle SNP (Supplementary Fig. 1), whilst the chromosome 5 locus
(defined by the positions of the first and last SNPs reaching
p < 1.00E5 in the region) encompasses 79 SNPs extending across
and upstream of the IL5 gene. When considering associations with
eosinophil count, one locus, including 14 SNPs, reached the thresh-
old for replication but not array-wide significance (Fig. 1, Lower
panel and Table 2) in both the basic and extended models (Table 2).
This locus is also on chromosome 5 and extends across the IL5
gene.
3.2. Genetic architecture of IL5 and eosinophil-associated loci
Given that only a single SNP was genotyped in the chromosome
14 locus, it is hard to say anything about the genetic architecture of
this locus. More genotyping in this region would be needed to fur-
ther explore this locus.
The 2 loci on chromosome 5 discovered here are located in
physical proximity to each other, however the SNPs in the 2 loci
are distinct and appear to be independent from each other by
linkage disequilibrium (LD, Fig. 2, Upper and Lower panels,Supplementary Fig. 2). The 3 genetic markers in the vicinity of
the IL5 gene reported in earlier studies were independent from
each other and the loci identified in the current study as assessed
by LD (Supplementary Fig. 2), however the eosinophil-associated
SNP (rs4143832) and the CVD-associated SNP (rs2706399) fell
within our eosinophil-associated locus. To further test the inde-
pendence of the 2 loci, conditional analysis was conducted,
whereby the IL-5 analysis was adjusted for the lead eosinophil-
associated SNP and vice versa. As demonstrated in Table 3, there
is negligible attenuation of the effect of the IL-5-associated SNPs
on IL-5 levels when including the lead eosinophil-associated SNP
as a covariate. The same is observed if the reverse is attempted,
thus we conclude that the loci are independent.
3.3. Replication of IL5-associated loci
Ideally we would have liked to replicate both the IL-5 and eosi-
nophil findings but due to lack of applicable cohorts it was only
possible to attempt replication for the IL-5-assocaited SNPs. Char-
acteristics of the replication cohorts are presented in Supplemen-
tary Table 1. Replication was attempted in 2 independent
European cohorts for the IL-5-associated loci, namely rs56183820
on chromosome 5 and rs4902762 on chromosome 14. The size of
effect in the replication meta-analysis (Table 4) was similar to that
seen in the discovery analysis, however the direction was inconsis-
tent and the associations were solidly non-significant.
3.4. IL-5 and eosinophil-associated SNPs in relation to IMT
Our aim was to use a Mendelian randomization approach to
assess whether the IL-5 or eosinophil-associated loci influenced
measures of IMT. As we were not able to replicate the association
of the chr 5 locus with IL-5 levels, conducting a Mendelian ran-
domization experiment was unjustified. However, we did assess
the effect of these SNPs on IMT measures. Considering 6 indepen-
dent loci (3 previously reported SNPs, 1 eosinophil-associated
locus and 2 IL-5-associated loci), the Bonferroni-corrected signifi-
cance threshold was set at p < 0.0083. No associations were
observed between the SNPs and baseline measures of IMT (Supple-
mentary Table 2). Eosinophil-associated SNPs demonstrated
nominally significant associations with progression of IMT-CCmax,
but only rs2706399 (the G allele of which was previously associ-
ated with increased CVD risk [6]) met the Bonferonni-corrected p
for significance (G allele, Beta 0.008, 95%CI (0.012, 0.004),
p = 0.0017, Supplementary Table 3). Further adjustment for emerg-
ing or established CVD risk markers had negligible effect on the
associations (Supplementary Table 3). Inclusion of eosinophil
count in the model rendered the eosinophil-associated SNPs non-
significant, but did not have an effect on the association of
rs2706399 (CVD-associated) with IMT-CCmax progression (Supple-
mentary Table 3).
3.5. Expression QTL
To identify functional effects of the IL-5 or eosinophil-
associated loci, SNPs which met the threshold for p < 1.00E5 were
examined for influence on expression of genes at the locus. In the
ASAP study, aorta (adventitia and media) and heart tissues were
examined. A region 250 kb up and downstream of the lead SNP
was defined for each locus, and genes within this region were
assessed for genotype-specific expression. Bonferroni correction
was made for 3 tissues and 4 loci (one on chromosome 14, 3 on
chromosome 5, p for significance <0.0042, (Supplementary
Fig. 2)). The chromosome 14 region included 2 genes, CTAGE5
and FBXO33 and rs4902762 was associated with CTAGE5
expression levels in heart tissue (p = 0.0073), but this did not reach
Fig. 1. Manhattan plots of associations between SNPs on the combined chip with (A) plasma IL-5 levels and (B) eosinophil count. Associations were adjusted for age, sex and
population stratification. The horizontal line at log10 p value = 5 indicates the threshold for replication.
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associated loci overlapped to a large degree, and included many
genes (P4HA2 and PDLIM4 (eosinophil count locus), SLC22A4,
SLC22A5, IRF1, IL5, RAD50, IL13, IL4, KIF3A and SEPT8 (both loci),
SHROOM1, GDF9, UQCRQ, LEAP2 and AFF4 (IL-5 locus).
Rs12652920 was associated with RAD50 expression in aortic media
(p = 0.0093), but this did not reach the level of statistical signifi-
cance. The MuTHER lymphocyte data [32] supports a positive
effect of the rs4705959 T allele (associated with increased eosino-
phil count) on mRNA expression of RAD50 and SLC22A5, but a neg-
ative effect on expression of IL5 (Table 5). The C allele of
rs12652920 (associated with increased IL-5 levels) was also associ-
ated with increased mRNA expression of RAD50 (Table 5). TherSNPBase was queried to identify proxies (r2 > 0.8) for the lead
SNPs and whether they have been reported to influence expression
of genes. For the IL-5-associated locus (rs56183420) 63 proxies
were identified, of which 47 reported eQTL effects on RAD50 but
only 24 for IL5. Of note, 35 of these SNPs were available in the
IMPROVE cohort, all showed associations (p < 1.00E4) with IL-5
levels, but not eosinophil count. For the eosinophil-associated
locus (rs72797327) 4 proxies were identified, of which 2 each were
reported for effects on IL-5 and RAD50 expression, but all 4
reported effects on SEPT8 expression. Of these SNPS, all 3 that were
available in IMPROVE showed strong (p < 1.00E5) effects on eosi-
nophil but not IL-5 levels. Considering the chromosome 14 locus,
23 proxies were identified with 5 influencing CTAGE5 expression
Table 2
Associations reaching the threshold for replication with IL5 levels or eosinophil count.
IL-5 (n = 3433) Eosinophils (n = 2365)
Basic model Extended model Basic model Extended model
Trait SNP CHR MAF MA RA BETA SE P BETA SE P BETA SE P BETA SE P
Eonsinophil rs72797327 5 0.249 G A 0.05 0.02 0.0249 0.05 0.02 0.0427 0.10 0.02 1.41E06 0.08 0.02 5.83E05
rs57896917 5 0.250 T A 0.05 0.02 0.0255 0.05 0.02 0.0438 0.10 0.02 1.35E06 0.08 0.02 5.60E05
rs11739623 5 0.244 T C 0.05 0.02 0.0413 0.04 0.02 0.0670 0.09 0.02 7.28E06 0.08 0.02 4.35E05
rs4705959 5 0.244 C T 0.05 0.02 0.0349 0.04 0.02 0.0565 0.09 0.02 5.81E06 0.09 0.02 3.46E05
IL5 rs12652920 5 0.221 C G 0.11 0.02 8.20E06 0.11 0.02 6.30E06 0.05 0.02 0.0441 0.04 0.02 0.0579
rs2706338 5 0.215 T C 0.11 0.02 8.55E06 0.11 0.02 6.23E06 0.05 0.02 0.0534 0.04 0.02 0.0692
rs56183820 5 0.220 T C 0.11 0.02 6.73E06 0.11 0.02 5.58E06 0.05 0.02 0.0207 0.05 0.02 0.0264
rs2158177 5 0.213 G A 0.11 0.02 6.87E06 0.11 0.02 7.04E06 0.05 0.02 0.0233 0.05 0.02 0.0300
rs1881457 5 0.215 C A 0.11 0.02 9.86E06 0.11 0.02 1.11E05 0.05 0.02 0.0363 0.04 0.02 0.0496
rs4902762 14 0.156 A G 0.12 0.03 5.76E06 0.12 0.03 1.08E05 0.01 0.03 0.6667 0.02 0.02 0.3916
Where: Trait, trait with which the locus is associated; MAF, minor allele frequency; MA, minor allele; RA, reference allele; basic model, adjustment for age, sex and population
structure; extended, adjustment for age, sex, population structure and (for IL5 analysis) lipids and crp or (for eosinophil count analysis) white blood cell count and proinsulin.
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IMPROVE and was associated with IL-5 levels but not eosinophil
count.
4. Discussion
This study identified genetic regulators of plasma IL-5 levels
and eosinophil count, however the lack of replication of the genetic
associations precludes the ability to formally assess the causality of
IL-5 levels on IMT. To the best of our knowledge this is the largest
study with measurement of IL-5 levels and the first to investigate
genetic regulation of IL-5 levels.
The genetic loci associated with IL-5 levels and eosinophil count
are in close proximity to each other and in the vicinity of the IL5
gene on chromosome 5, but act independently. Earlier studies
identified SNPs in the region of the IL5 and IL5a genes as being
associated with inflammatory bowel disease (rs2188962 [34]),
eosinophil count (rs4143832 [14]) and coronary artery disease
(rs2706399 [6]). These variants were present on the combined chip
and thus were also analysed. No association was observed between
rs2706399 and either IL-5 levels or eosinophil count (Supplemen-
tary Table 5). In contrast, rs2188962 demonstrated nominal associ-
ations and rs4143832 demonstrated convincing associations with
IL-5 levels and eosinophil count (Supplementary Table 5). In agree-
ment with Gudbjartsson et al., the minor allele of rs4143832 was
associated with eosinophil count [14] as well as IL-5 levels. Of note,
whilst these SNPs demonstrate some significance in relation to
levels of IL-5 or eosinophil count, they do not reach the preset level
of significance for being forwarded to replication analysis.
Rs4143832 and rs2706399 are located within the eosinophil-
associated locus reported here but are independent from the SNPs
studied here (by LD, Supplementary Table 2).
Whilst SNPs at the loci identified here do show some associa-
tions with IL5 mRNA levels, expression of the RAD50 gene demon-
strates stronger and more consistent associations across the loci.
The results from rSNPBase are less clear, and whilst they do sup-
port RAD50 as a possible candidate, they suggest that SEPT8 (chro-
mosome 5) and FBXO33 (chromosome 14) might also be relevant.
Recently, up-regulation of RAD50 and other double-strand repair
proteins was reported in vascular smooth muscle cells from
atherosclerotic plaque [35]. The authors suggest that these pro-
teins are associated with plaque stability rather than atherosclero-
sis. Thus it is plausible that the IL5 locus influences plaque stability
via RAD50-associated mechanisms rather than IL-5-associated
mechanisms. This speculative mechanism fits with the IL5 locus
being associated with MI [6] and unstable angina [36], typicallyresulting from plaque rupture, but not with IMT, which is indica-
tive of vessel wall remodelling.
Eosinophil count and IL-5 levels are closely inter-connected: IL-
5 is essential for eosinophil maturation and differentiation [37].
Conversely, eosinophil-specific granules store IL-5 [38], indicating
that these cells might also contribute to increasing circulating IL-
5 levels. In IMPROVE, there is a strong correlation between IL-5
concentrations and eosinophil count (Spearmans rho = 0.560,
p < 0.001) [11]. Thus it is interesting that these 2 variables are reg-
ulated by independent loci in the same genetic region. One possi-
bility is that a common factor, potentially RAD50, regulates both
IL-5 levels and eosinophil count. An alternative scenario is that,
given the roles of IL-5 and eosinophils in inflammation, upregula-
tion of RAD50 might be a DNA-protective stress response mecha-
nism. This would explain the puzzling finding that the allele
associated with increased eosinophil count shows increased
RAD50 and the inverse effect on IL5 gene expression, whilst the
allele associated with increased IL-5 levels also shows increased
RAD50 gene expression. It is of note that 2 of the top eQTL SNPs
for RAD50 [39] are those with the strongest associations with eosi-
nophils (rs11739623 and rs4705959) in IMPROVE. Previous reports
have demonstrated the use of studying specific immune cell types
to explore immune or inflammation-related diseases [40,41].
Whilst the relationship between the SNPs, RAD50 expression, IL-5
levels and eosinophil counts requires clarification, these findings
are of potential relevance for eosinophil-associated disorders.
Whilst this is the largest study with detailed IMT measures,
plasma IL-5 concentrations and extensive genetic data for all sub-
jects, there are limitations to the study. This study was conducted
in subjects with at least 3 classical CVD risk factors, thus findings
might not pertain to other populations. A sex difference in IL-5
levels has been reported [11], thus sex-stratified analyses would
be of interest. However, this approach has not been used here,
for two reasons: the distribution of outliers (P1.5 interquartile
range above the upper quartile) between men and women might
explain the sex difference in levels. Because of this and the loss
of power when stratifying the analyses, we believe that the chance
of detecting false positive signals is too high for this analysis to be
robust. The lack of Th2 count or measurements of Th2 cytokines
mean that we cannot conclusively determine the origin of IL-5
and whether Th2 responses are activated in these subjects. How-
ever, it has previously been shown that the percentage of Th2 cells
has only a very weak (non significant) correlation with IL-5 levels
released by activated leukocytes [28]. The genotyping chips
employed in this study are based on a large scale candidate
gene/loci experiment, which allows a less stringent significance
Fig. 2. Regional plot of SNPs in the chromosome 5 loci which are associated with (A) circulating IL-5 concentrations and (B) eosinophil count. The purple diamond indicates
rs12652920 (the lead SNP in the IL-5-associated locus), and thus demonstrates that the lead SNP in the eosinophil-associated locus (rs57896917) is independent by linkage
disequilibrium.
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not represented. Thus we cannot comprehensibly describe the
genetic architecture of the IL-5-associated locus on chromosome14, nor can we exclude the possibility that true IL-5-influencing
genetic variants exist which lie within areas of the genome not
examined in this study.
Table 3
Association conditional on a top SNP from the neighbour loci.
IL5 (n = 3433) Eosinophils (n = 2365)
Basic +Lead eosinophil-
associated SNP
(rs57896917)
Asmds +Lead IL5-associated
SNP (rs56183820)
Trait SNP CHR MAF MA RA BETA SE P BETA SE P BETA SE P BETA SE P
Eonsinophil rs72797327a 5 0.249 G A 0.05 0.02 0.0249 na na na 0.10 0.02 1.41E06 0.09 0.02 9.90E06
rs57896917 5 0.250 T A 0.05 0.02 0.0255 na na na 0.10 0.02 1.35E06 0.09 0.02 9.51E06
rs11739623 5 0.244 T C 0.05 0.02 0.0413 0.14 0.11 0.1999 0.09 0.02 7.28E06 0.09 0.02 4.60E05
rs4705959 5 0.244 C T 0.05 0.02 0.0349 0.11 0.11 0.2989 0.09 0.02 5.81E06 0.09 0.02 3.74E05
IL5 rs12652920 5 0.221 C G 0.11 0.02 8.20E06 0.10 0.02 4.26E05 0.05 0.02 0.0441 0.04 0.10 0.6932
rs2706338 5 0.215 T C 0.11 0.02 8.55E06 0.10 0.02 4.31E05 0.05 0.02 0.0534 0.04 0.07 0.5655
rs56183820 5 0.220 T C 0.11 0.02 6.73E06 0.10 0.02 3.99E05 0.05 0.02 0.0207 na na na
rs2158177 5 0.213 G A 0.11 0.02 6.87E06 0.10 0.02 3.85E05 0.05 0.02 0.0233 0.05 0.09 0.5677
rs1881457 5 0.215 C A 0.11 0.02 9.86E06 0.10 0.02 5.51E05 0.05 0.02 0.0363 0.04 0.08 0.6372
Where: Trait, trait with which the locus is associated; MAF, minor allele frequency; MA, minor allele; RA, reference allele; basic model, adjustment for age, sex and population
structure; na, not applicable.
a rs72797327 is in almost complete LD (r2 = 0.99) with the SNP included as a covariate, thus results are not reported for this SNP.
Table 4
Replication meta-analysis of IL5-associated genetic variants.
Basic model Extended model
SNP CHR MAF MA RA BETA SE P Direction I2 I2_p BETA SE P Direction I2 I2_p
rs56183820 5 0.21 T C 0.04 0.04 0.2763 + 23.9 0.2516 0.05 0.04 0.2517 + 32.3 0.2242
rs4902762 14 0.14 A G -0.02 0.05 0.6568  0 0.5668 0.02 0.05 0.6111  0 0.4814
Where: MAF, minor allele frequency; MA, minor allele; RA, reference allele; basic model, adjustment for age, sex and population structure; extended, adjustment for age, sex,
population structure, lipids and crp; direction, direction of minor allele effect; I2, I squared measure of heterogeneity; I2_p, P for heterogeneity. Cohorts included in the meta-
analysis are MDC and PROCARDIS.
Table 5
Effect of alleles associated with increased eosinophil counts or IL-5 levels on gene expression in the MuTHER lymphocyte dataset.
Trait SNP CHR SNP_INFO Gene EA EAF BETA SE P
Eonsinophil rs11739623 5 0.999 RAD50 T 0.252 0.23 0.02 1.74E29
SLC22A5 T 0.252 0.05 0.01 4.75E04
IL5 T 0.252 0.02 0.01 8.52E04
P4HA2 T 0.252 0.07 0.02 0.0026
rs4705959 5 0.996 RAD50 T 0.749 0.23 0.02 2.06E29
SLC22A5 T 0.749 0.05 0.01 2.95E04
IL5 T 0.749 0.02 0.01 6.52E04
P4HA2 T 0.749 0.08 0.02 0.0021
IL5 rs12652920 5 0.977 RAD50 G 0.808 0.10 0.02 8.64E06
P4HA2 G 0.808 0.07 0.03 0.0072
rs2706338 5 0.986 RAD50 T 0.194 0.10 0.02 1.02E05
P4HA2 T 0.194 0.07 0.03 0.0095
rs4902762 14 0.95 TRAPPC6B G 0.841 0.05 0.01 0.0013
PNN G 0.841 0.09 0.03 0.0066
Where: EA, Effect allele; EAF, effect allele frequency; The rs4705959 T allele was associated with increased eosinophil levels; The rs12652920 C allele was associated with
increased IL-5 levels.
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This study identified genetic loci on chromosome 5 associated
with IL-5 levels and eosinophil count. Whilst these loci are close
together in the vicinity of the IL5 gene, they are independent. Fur-
thermore, expression analysis suggests RAD50, rather than IL5, as a
prime candidate gene for these associations. An additional locus
associated with IL-5 levels was observed on chromosome 14. This
report suggests that these loci have negligible influence on IMT
measures.
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